We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
- Authors
Gantenbein, Andreas R.; Bonvin, Christophe; Kamm, Christian P.; Schankin, Christoph J.; Zecca, Chiara; Zieglgänsberger, Dominik; Merki-Feld, Gabriele Susanne; Pohl, Heiko; Rudolph, Nicole; Ryvlin, Philippe; Agosti, Reto; Schäfer, Elisabeth; Meyer, Ina; Kulartz-Schank, Monika; Arzt, Michael E.
- Abstract
Background: There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life. Objective: This 18-month interim analysis of 172 patients with episodic or chronic migraine from the SQUARE study provides first prospective insights on the impact of mandatory erenumab treatment interruption, following Swiss-reimbursement requirements, in a real-world clinical setting in Switzerland. Findings: Recruited patients receiving 70 or 140 mg erenumab underwent treatment interruption on average 11.2 months after therapy onset with a mean duration of 4 months. There were sustained improvements in mean monthly migraine days (MMD) and migraine disability (mMIDAS) during initial treatment with erenumab. Treatment interruption was associated with a temporary worsening of condition. Symptoms ameliorated upon therapy reuptake reaching improvements similar to pre-break within 3 months. Conclusions: Treatment interruption was associated with a temporary worsening of condition, which improved again after therapy restart.
- Subjects
CALCITONIN gene-related peptide; ERENUMAB; MIGRAINE; MONOCLONAL antibodies; QUALITY of life
- Publication
Journal of Neurology, 2024, Vol 271, Issue 8, p5402
- ISSN
0340-5354
- Publication type
Article
- DOI
10.1007/s00415-024-12470-6